CMOPF (Cosmo NV) ROCE %: -0.07% (As of Dec. 2025)


CMOPF Cosmo NV CMOPF
82 GF Score
Price $85.45
GF Value $54.86
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cosmo NV ROCE %?

Cosmo NV CMOPF +4.87% 82 ROCE % is -0.07% as of Dec. 2025. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $54.86 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cosmo NV's annualized ROCE % for the quarter that ended in Dec. 2025 was -0.07%.

Cosmo NV  (OTCPK:CMOPF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cosmo NV ROCE % Related Terms

Cosmo NV ROCE % Historical Data

* Premium members only.

The historical data trend for Cosmo NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosmo NV ROCE % Chart

Cosmo NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.70 4.80 0.39 27.39 -0.14

Cosmo NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.39 29.09 23.97 -0.22 -0.07
CMOPF
82GF Score
Cosmo NV CMOPF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosmo NV ROCE % Calculation

Cosmo NV's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-0.934/( ( (677.248 - 50.542) + (717.374 - 29.885) )/ 2 )
=-0.934/( (626.706+687.489)/ 2 )
=-0.934/657.0975
=-0.14 %

Cosmo NV's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-0.448/( ( (703.956 - 56.193) + (717.374 - 29.885) )/ 2 )
=-0.448/( ( 647.763 + 687.489 )/ 2 )
=-0.448/667.626
=-0.07 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -0.07% mean?
Cosmo NV (CMOPF) has a ROCE % of -0.07% as of Dec. 2025.
Is Cosmo NV's ROCE % too high?
Cosmo NV's current ROCE % is -0.07%. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's ROCE % compare to LLY and JNJ?
Cosmo NV's ROCE % of -0.07% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current ROCE % is -0.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.86, compared to a current price of $85.45 — trading 55.8% above its estimated fair value. The current ROCE % is -0.07%. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current ROCE % is -0.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosmo NV (CMOPF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued. The current stock price of $85.45 is trading 55.8% above its estimated GF Value™ of $54.86. GuruFocus considers Cosmo NV to be Significantly Overvalued.

Key valuation signals for CMOPF:

  • ROCE %: -0.07%
  • GF Value™: $54.86 vs. price of $85.45 (55.8% above fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosmo NV Business Description

Address 91/94 North Wall Quay, 7th Floor, One North Dock, Dublin, IRL, D01 H7V7
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score

Get the complete analysis for CMOPF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$85.45
Price
$54.86
GF Value